ChoroidNCT07376005
Effects of Acute Sugar Intake on Choroidal Thickness
A study testing Oral glucose in people with Choroid, run by Southern College of Optometry at 1 site in United States.
Trial summary
This study aims to bridge that gap by investigating how acute sugar intake influences choroidal thickness. Read more about this study
- Who is it for?
- Ages 21 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Choroid
- What is being tested?
- Oral glucose
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 47 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2026to May 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- In order to be eligible for enrolment, each subject must have less than 6 diopters of spherical equivalent refractive error, and have no existing diagnosis of diabetes or pre-diabetes.
Who cannot join
- Any potential subject with known retinal pathology will be excluded. Any potential subject with any other known systemic or ocular conditions that may impact their ability to participate in the study or provide generalizable data will also be excluded.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Southern College of Optometry
Memphis, Tennessee, 38111
Morgan Ollinger, OD, MS, 9017223377, mollinger@sco.edu
About this study
This study aims to bridge that gap by investigating how acute sugar intake influences choroidal thickness.
Read the detailed description
This investigation will be a prospective, repeated-measures study. All subjects will arrive fasted and will be asked not to consume any outside food or beverages during the three-hour study period, and will be asked to abstain from caffeine intake for 12 hours before participation. A baseline OCT scan of the macula of the right eye will be performed using the Heidelberg Spectralis OCT system. Participants will then consume 30 grams of sugar in the form of glucose tablets. Macular OCT scans of the right eye will be repeated every 30 minutes for 3 hours following sugar consumption.
- Conditions
- Choroid
- Being tested
- Oral glucose
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oral glucoseDietary supplement
Participants will consume 30 grams of sugar in the form of glucose tablets.
| Study group | Role | What they receive |
|---|---|---|
| Oral glucose | Active comparator | Subjects receive 30g of oral glucose Receives: Dietary Supplement: Oral glucose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in choroidal thickness
The primary outcome for this investigation will be changes in choroidal thickness from baseline across timepoints.
Measured: within 3 hours of baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jan 2026
- Study startJan 2026 (estimated)
- Primary completionMay 2026 (estimated)
- Study completionMay 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ChoroidStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 47 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Southern College of Optometry
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07376005
- Sponsor's protocol ID
- 2025-12-01PS
- Status last verified
- Jan 2026
- First submitted
- 21 Jan 2026
- Last updated
- 29 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Acute Sugar Intake on Choroidal Thickness
- ClinicalTrials.gov ID
- NCT07376005
- Acronym / sponsor ID
- 2025-12-01PS
- Conditions
- Choroid
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 47 participants (estimated)
- Lead sponsor
- Southern College of OptometryUniversity, hospital or other
- Study start
- Jan 2026 (estimated)
- Primary completion
- May 2026 (estimated)
- Study completion
- May 2026 (estimated)
- First posted
- 29 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to bridge that gap by investigating how acute sugar intake influences choroidal thickness.
Detailed description
This investigation will be a prospective, repeated-measures study. All subjects will arrive fasted and will be asked not to consume any outside food or beverages during the three-hour study period, and will be asked to abstain from caffeine intake for 12 hours before participation. A baseline OCT scan of the macula of the right eye will be performed using the Heidelberg Spectralis OCT system. Participants will then consume 30 grams of sugar in the form of glucose tablets. Macular OCT scans of the right eye will be repeated every 30 minutes for 3 hours following sugar consumption.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Oral glucose | Active comparator | Dietary Supplement: Oral glucoseSubjects receive 30g of oral glucose |
Who may qualify
- Ages
- 21 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- In order to be eligible for enrolment, each subject must have less than 6 diopters of spherical equivalent refractive error, and have no existing diagnosis of diabetes or pre-diabetes.
Key exclusion criteria (1 listed)
- Any potential subject with known retinal pathology will be excluded. Any potential subject with any other known systemic or ocular conditions that may impact their ability to participate in the study or provide generalizable data will also be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oral glucoseParticipants will consume 30 grams of sugar in the form of glucose tablets. | Dietary supplement | Oral glucose |
Primary outcome
Change in choroidal thickness
Time frame: within 3 hours of baseline
The primary outcome for this investigation will be changes in choroidal thickness from baseline across timepoints.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2026.
Related trials for Choroid
Not yet recruitingPhase 2
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
Neovascular Age Related Macular Degeneration(nAMD)
Not yet recruitingObservational study
Multimodal MRI Assessment of Brain Fluid Circulation in Idiopathic Intracranial Hypertension
Idiopathic Intracranial Hypertension
Active, not recruitingObservational study
Gyrate Atrophy Ocular and Systemic Study
Gyrate Atrophy, Gyrata of Choroid and Retina; Atrophy
Active, not recruitingPhase 2
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular Age-related Macular Degeneration
RecruitingPhase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Central Nervous System Neoplasms, Glioblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Oral glucose in people with Choroid, run by Southern College of Optometry at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Morgan Ollinger, OD, MS (9017223377, mollinger@sco.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in choroidal thickness (time frame: within 3 hours of baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2026.